Tiziana Life Sciences LtdNASDAQ:TLSANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8200
- TODAY'S CHANGE (%)0.0500 (6.4935%)
- Bid / Lots0.7810/ 20
- Ask / Lots0.8400/ 5
- Open / Previous Close0.7900 / 0.7700
- Day Range
- 52 Week Range
- Volume120,805
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 32671 | 0.758 |
| 09:36 ET | 100 | 0.79 |
| 09:38 ET | 100 | 0.7999 |
| 09:39 ET | 257 | 0.7901 |
| 09:41 ET | 200 | 0.7902 |
| 09:43 ET | 300 | 0.790101 |
| 09:50 ET | 100 | 0.7999 |
| 09:56 ET | 100 | 0.7998 |
| 09:57 ET | 2706 | 0.7997 |
| 10:01 ET | 1100 | 0.796299 |
| 10:03 ET | 15131 | 0.82 |
| 10:06 ET | 10210 | 0.7951 |
| 10:08 ET | 612 | 0.799864 |
| 10:17 ET | 450 | 0.7952 |
| 10:24 ET | 1001 | 0.7953 |
| 10:51 ET | 170 | 0.7953 |
| 10:53 ET | 5337 | 0.7951 |
| 11:08 ET | 500 | 0.7956 |
| 11:27 ET | 5044 | 0.7951 |
| 11:40 ET | 500 | 0.82 |
| 11:54 ET | 129 | 0.81 |
| 12:05 ET | 100 | 0.81 |
| 12:07 ET | 4100 | 0.82 |
| 12:30 ET | 100 | 0.81 |
| 12:32 ET | 9999 | 0.79 |
| 01:17 ET | 1928 | 0.82 |
| 01:28 ET | 1500 | 0.8051 |
| 01:30 ET | 3951 | 0.7902 |
| 02:18 ET | 150 | 0.7976 |
| 02:33 ET | 2575 | 0.7902 |
| 02:45 ET | 1540 | 0.8051 |
| 03:00 ET | 497 | 0.79992 |
| 03:25 ET | 121 | 0.805 |
| 03:36 ET | 100 | 0.7999 |
| 03:41 ET | 1774 | 0.7903 |
| 03:48 ET | 100 | 0.8 |
| 03:50 ET | 100 | 0.799 |
| 03:52 ET | 300 | 0.8 |
| 03:54 ET | 100 | 0.8 |
| 03:56 ET | 100 | 0.82 |
| 03:57 ET | 200 | 0.8199 |
| 03:59 ET | 6277 | 0.82 |
May 13, 2024
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab, from 7:00AM ET on Monday May 13, 2024 by Dow Jones
7:00AM ET on Monday May 13, 2024 by Dow Jones
Apr 25, 2024
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab, from 10:00AM ET on Thursday Apr 25, 2024 by Dow Jones
10:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 23, 2024
Apr 22, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 79.4M | -5.5x | --- |
Aileron Therapeutics Inc | 79.7M | -1.2x | --- |
Passage Bio Inc | 80.7M | -0.8x | --- |
Entera Bio Ltd | 82.3M | -8.4x | --- |
Provectus Biopharmaceuticals Inc | 79.7M | -28.7x | --- |
Cognition Therapeutics Inc | 84.1M | -2.5x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Kunwar Shailubhai
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-0.15 |
Book Value | $0.19 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
